Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVASTEM: Bevacizumab in Neoadjuvant Breast Cancer
NCT01190345Phase 2Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- May 2010
- Primary completion
- Jul 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in breast cancer (2 arms), sponsored by Institut Paoli-Calmettes. Primary endpoint: Measure of the anti-cancer stem cell activity at 4 months. Started May 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01190345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01190345.